The effect of neuroendocrine differentiation on the survival of patients diagnosed with pancreatic ductal adenocarcinoma-Reference-Cited by-同舟云学术

The effect of neuroendocrine differentiation on the survival of patients diagnosed with pancreatic ductal adenocarcinoma

Published:2020-12-23 Issue:12 Volume: Page:38-44
ISSN:1682-8658
Container-title:Experimental and Clinical Gastroenterology
language:
Short-container-title:jour

Author:

Kit O. I.¹,Franciyanc E. M.¹,Derizhanova I. S.²,Karnaukhov N. S.¹,Kuznetsova M. A.¹,Voloshin M. V.²^ORCID,Trifanov V. S.¹,Aleinov V. I.¹

Affiliation:

1. National medical research centre for oncology of the Ministry of Health of the Russian Federation

2. Rostov State Medical University of the Ministry of Health of the Russian Federation

Abstract

Purpose of the study. Determine the frequency of MiNeN among pancreatic carcinomas and analyze the survival rate of patients depending on the percentage of cells with neuroendocrine differentiation in the tumor.Materials and methods. The current study included 31 patients with a pancreatic tumor who received surgical treatment at the Rostov Cancer Research Institute. An immunohistochemical study was conducted on biomarkers of chromogranin A, synaptophysin, and ki-67 for these patients. Based on the data obtained, 4 groups for neuroendocrine differentiation were identified.Results. The direct effect of neuroendocrine differentiation on the survival of patients with histologically confirmed pancreatic ductal adenocarcinoma has been proven. Among the sample of 31 patients, neuroendocrine differentiation was revealed in 24 cases (77%), of which 3 cases of MiNeN (10.3%) were detected. It is also proven relationship between neuroendocrine and patient survival, where an increase percent of positive cells in tumors (chromogranin A or synaptophysin) means a better prognosis. Chromogranin A is a more significant predictor of survival compared to synaptophysin. The largest difference in survival was between negative expression of chromogranin A and the presence of more than 1% positive cells in the tumor.Conclusion. We supposed that it is necessary to use neuroendocrine markers (chromogranin A and synaptophysin) in the diagnosis of ductal adenocarcinomas, even without histological signs of neuroendocrine differentiation. This will allow for a larger amount of data to determine their significance as prognostic markers.

Publisher

LLC Global Media Technology

Subject

General Medicine

Reference25 articles.

1. Davydov M. I., Aksel’ E. M. Statistika zlokachestvennyh novoobrazovanij v Rossii i stranah SNG v 2012 g [Statistics of malignant neoplasms in Russia and the CIS countries in 2012]. Moscow, RONC Publishing Group, 2014. 226 p.

2. Delektorskaya V. V. Nejroendokrinnye novoobrazovaniya podzheludochnoj zhelezy: novye aspekty morfologicheskoj klassifi kacii (Vsemirnaya organizaciya zdravoohraneniya, 2017) [Pancreatic neuroendocrine neoplasms: new aspects of morphological classifi cation (World Health Organization, 2017)]. Uspekhi molekulyarnoj onkologii – Advances in molecular oncology, 2017;4(3):104–108.

3. Kubyshkin VA, Kochatkov AV, Konstantinova MM, Kriger AG. The terminology, classifications and staging of neuroendocrine tumors of the pancreas. Pirogov Russian Journal of Surgery = Khirurgiya. Zhurnal imeni N. I. Pirogova. 2012;(6):4–8.

4. Chernousov AF, Egorov AV, Musaev GKh, et al. Neuroendocrine tumors of a pancreas: 30 year’s experience of clinic of faculty surgery of N. N. Burdenko. Pirogov Russian Journal of Surgery = Khirurgiya. Zhurnal imeni N. I. Pirogova. 2013;(7):13–19.

5. Kit O. I., Derizhanova I. S., Karnauhov N. S., et al. Skrining nejroendokrinnogo komponenta v rake zheludka [Screening of the neuroendocrine component in gastric cancer]. Sovremennye problemy nauki i obrazovaniya – Modern problems of science and education, 2016, no. 5, 3 p.